Peripheral inflammatory immune response differs among sporadic and familial Parkinson’s disease
Abstract Peripheral inflammatory immune responses are thought to play a major role in the pathogenesis of Parkinson’s disease (PD). The neutrophil-to-lymphocyte ratio (NLR), a biomarker of systemic inflammation, has been reported to be higher in patients with PD than in healthy controls (HCs). The p...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-01-01
|
| Series: | npj Parkinson's Disease |
| Online Access: | https://doi.org/10.1038/s41531-023-00457-5 |
| _version_ | 1797421458005164032 |
|---|---|
| author | Laura Muñoz-Delgado Daniel Macías-García María Teresa Periñán Silvia Jesús Astrid D. Adarmes-Gómez Marta Bonilla Toribio Dolores Buiza Rueda María del Valle Jiménez-Jaraba Belén Benítez Zamora Rafael Díaz Belloso Sergio García-Díaz Miguel Martín-Bórnez Rocío Pineda Sánchez Fátima Carrillo Pilar Gómez-Garre Pablo Mir |
| author_facet | Laura Muñoz-Delgado Daniel Macías-García María Teresa Periñán Silvia Jesús Astrid D. Adarmes-Gómez Marta Bonilla Toribio Dolores Buiza Rueda María del Valle Jiménez-Jaraba Belén Benítez Zamora Rafael Díaz Belloso Sergio García-Díaz Miguel Martín-Bórnez Rocío Pineda Sánchez Fátima Carrillo Pilar Gómez-Garre Pablo Mir |
| author_sort | Laura Muñoz-Delgado |
| collection | DOAJ |
| description | Abstract Peripheral inflammatory immune responses are thought to play a major role in the pathogenesis of Parkinson’s disease (PD). The neutrophil-to-lymphocyte ratio (NLR), a biomarker of systemic inflammation, has been reported to be higher in patients with PD than in healthy controls (HCs). The present study was aimed at determining if the peripheral inflammatory immune response could be influenced by the genetic background of patients with PD. We included a discovery cohort with 222 patients with PD (132 sporadic PD, 44 LRRK2-associated PD (with p.G2019S and p.R1441G variants), and 46 GBA-associated PD), as well as 299 HCs. Demographic and clinical data were recorded. Leukocytes and their subpopulations, and the NLR were measured in peripheral blood. Multivariate lineal regression and post-hoc tests were applied to determine the differences among the groups. Subsequently, a replication study using the Parkinson’s Progression Markers Initiative cohort was performed which included 401 patients with PD (281 sPD patients, 66 LRRK2-PD patients, 54 GBA-PD patients) and a group of 174 HCs. Patients with sporadic PD and GBA-associated PD showed a significantly lower lymphocyte count, a non-significantly higher neutrophil count and a significantly higher NLR than HCs. The peripheral inflammatory immune response of patients with LRRK2-associated PD did not differ from HCs. Our study supports the involvement of a peripheral inflammatory immune response in the pathophysiology of sPD and GBA-associated PD. However, this inflammatory response was not found in LRRK2-associated PD, probably reflecting different pathogenic inflammatory mechanisms. |
| first_indexed | 2024-03-09T07:17:43Z |
| format | Article |
| id | doaj.art-52eba1144fa34462b2f4bc237ba2e7c9 |
| institution | Directory Open Access Journal |
| issn | 2373-8057 |
| language | English |
| last_indexed | 2024-03-09T07:17:43Z |
| publishDate | 2023-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Parkinson's Disease |
| spelling | doaj.art-52eba1144fa34462b2f4bc237ba2e7c92023-12-03T08:20:41ZengNature Portfolionpj Parkinson's Disease2373-80572023-01-01911910.1038/s41531-023-00457-5Peripheral inflammatory immune response differs among sporadic and familial Parkinson’s diseaseLaura Muñoz-Delgado0Daniel Macías-García1María Teresa Periñán2Silvia Jesús3Astrid D. Adarmes-Gómez4Marta Bonilla Toribio5Dolores Buiza Rueda6María del Valle Jiménez-Jaraba7Belén Benítez Zamora8Rafael Díaz Belloso9Sergio García-Díaz10Miguel Martín-Bórnez11Rocío Pineda Sánchez12Fátima Carrillo13Pilar Gómez-Garre14Pablo Mir15Unidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de SevillaUnidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de SevillaUnidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de SevillaUnidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de SevillaUnidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de SevillaUnidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de SevillaUnidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de SevillaUnidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de SevillaUnidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de SevillaUnidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de SevillaUnidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de SevillaUnidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de SevillaUnidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de SevillaUnidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de SevillaUnidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de SevillaUnidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de SevillaAbstract Peripheral inflammatory immune responses are thought to play a major role in the pathogenesis of Parkinson’s disease (PD). The neutrophil-to-lymphocyte ratio (NLR), a biomarker of systemic inflammation, has been reported to be higher in patients with PD than in healthy controls (HCs). The present study was aimed at determining if the peripheral inflammatory immune response could be influenced by the genetic background of patients with PD. We included a discovery cohort with 222 patients with PD (132 sporadic PD, 44 LRRK2-associated PD (with p.G2019S and p.R1441G variants), and 46 GBA-associated PD), as well as 299 HCs. Demographic and clinical data were recorded. Leukocytes and their subpopulations, and the NLR were measured in peripheral blood. Multivariate lineal regression and post-hoc tests were applied to determine the differences among the groups. Subsequently, a replication study using the Parkinson’s Progression Markers Initiative cohort was performed which included 401 patients with PD (281 sPD patients, 66 LRRK2-PD patients, 54 GBA-PD patients) and a group of 174 HCs. Patients with sporadic PD and GBA-associated PD showed a significantly lower lymphocyte count, a non-significantly higher neutrophil count and a significantly higher NLR than HCs. The peripheral inflammatory immune response of patients with LRRK2-associated PD did not differ from HCs. Our study supports the involvement of a peripheral inflammatory immune response in the pathophysiology of sPD and GBA-associated PD. However, this inflammatory response was not found in LRRK2-associated PD, probably reflecting different pathogenic inflammatory mechanisms.https://doi.org/10.1038/s41531-023-00457-5 |
| spellingShingle | Laura Muñoz-Delgado Daniel Macías-García María Teresa Periñán Silvia Jesús Astrid D. Adarmes-Gómez Marta Bonilla Toribio Dolores Buiza Rueda María del Valle Jiménez-Jaraba Belén Benítez Zamora Rafael Díaz Belloso Sergio García-Díaz Miguel Martín-Bórnez Rocío Pineda Sánchez Fátima Carrillo Pilar Gómez-Garre Pablo Mir Peripheral inflammatory immune response differs among sporadic and familial Parkinson’s disease npj Parkinson's Disease |
| title | Peripheral inflammatory immune response differs among sporadic and familial Parkinson’s disease |
| title_full | Peripheral inflammatory immune response differs among sporadic and familial Parkinson’s disease |
| title_fullStr | Peripheral inflammatory immune response differs among sporadic and familial Parkinson’s disease |
| title_full_unstemmed | Peripheral inflammatory immune response differs among sporadic and familial Parkinson’s disease |
| title_short | Peripheral inflammatory immune response differs among sporadic and familial Parkinson’s disease |
| title_sort | peripheral inflammatory immune response differs among sporadic and familial parkinson s disease |
| url | https://doi.org/10.1038/s41531-023-00457-5 |
| work_keys_str_mv | AT lauramunozdelgado peripheralinflammatoryimmuneresponsediffersamongsporadicandfamilialparkinsonsdisease AT danielmaciasgarcia peripheralinflammatoryimmuneresponsediffersamongsporadicandfamilialparkinsonsdisease AT mariateresaperinan peripheralinflammatoryimmuneresponsediffersamongsporadicandfamilialparkinsonsdisease AT silviajesus peripheralinflammatoryimmuneresponsediffersamongsporadicandfamilialparkinsonsdisease AT astriddadarmesgomez peripheralinflammatoryimmuneresponsediffersamongsporadicandfamilialparkinsonsdisease AT martabonillatoribio peripheralinflammatoryimmuneresponsediffersamongsporadicandfamilialparkinsonsdisease AT doloresbuizarueda peripheralinflammatoryimmuneresponsediffersamongsporadicandfamilialparkinsonsdisease AT mariadelvallejimenezjaraba peripheralinflammatoryimmuneresponsediffersamongsporadicandfamilialparkinsonsdisease AT belenbenitezzamora peripheralinflammatoryimmuneresponsediffersamongsporadicandfamilialparkinsonsdisease AT rafaeldiazbelloso peripheralinflammatoryimmuneresponsediffersamongsporadicandfamilialparkinsonsdisease AT sergiogarciadiaz peripheralinflammatoryimmuneresponsediffersamongsporadicandfamilialparkinsonsdisease AT miguelmartinbornez peripheralinflammatoryimmuneresponsediffersamongsporadicandfamilialparkinsonsdisease AT rociopinedasanchez peripheralinflammatoryimmuneresponsediffersamongsporadicandfamilialparkinsonsdisease AT fatimacarrillo peripheralinflammatoryimmuneresponsediffersamongsporadicandfamilialparkinsonsdisease AT pilargomezgarre peripheralinflammatoryimmuneresponsediffersamongsporadicandfamilialparkinsonsdisease AT pablomir peripheralinflammatoryimmuneresponsediffersamongsporadicandfamilialparkinsonsdisease |